Hong Kong stock movement: CSTONE PHARMA-B rises 16.21%, GIC and executives increase holdings showing confidence

Hong Kong Stock Movement

CSTONE PHARMA-B rose 16.21%. Based on recent news,

1. On November 10, the Government of Singapore Investment Corporation (GIC) increased its holdings in CSTONE PHARMA-B by 1.7955 million shares at a price of HKD 5.4692 per share, totaling approximately HKD 9.8199 million. GIC's continuous increase in holdings shows recognition of CSTONE PHARMA's long-term value.

2. On November 11, CSTONE PHARMA's executive director Yang Jian added 100,000 shares at an average price of HKD 5.345 per share, totaling HKD 534,500. The increase in executive holdings reflects confidence in the company's future development. The increase in international capital and management holdings shows confidence.

Stocks with High Trading Volume in the Industry

BeiGene fell 3.58%. Based on recent key news:

1. On November 13, BeiGene released its performance for the first three quarters of 2025, with net profit turning from loss to profit year-on-year, and the stock price rose 7.06%. The excellent performance drove the stock price up. Source: Jinwu Financial News

2. On November 12, Haitong International raised its revenue and net profit expectations for BeiGene over the next three years, reflecting better-than-expected growth in sales and R&D expenses. This move enhanced market confidence, leading to a rise in stock price. Source: Haitong International

3. On November 12, CMB International raised BeiGene's target price to HKD 231, maintaining a buy rating, reflecting a more optimistic expectation for operating expense ratios. This rating supports the rise in stock price. Source: Zhito Finance. The innovative drug industry is entering a new cycle driven by profitability.

3SBio rose 3.49%. Based on recent news:

1. On November 10, Huatai-PineBridge Fund increased its holdings in 3SBio by 1.471 million shares, raising its holding ratio to 6.04%. This increase shows institutional confidence in the company's future development, driving the stock price up.

2. Recently, 3SBio announced clinical phase II research data for 707 combination chemotherapy treatment for 1L NSCLC at the STIC conference, showing good efficacy and safety, supporting the continuation of clinical phase III research. This positive clinical progress boosted market confidence, driving the stock price up.

3. Guosen Securities released a research report, raising its profit forecast for 3SBio for 2025-2027 and maintaining an "outperform market" rating. Investment banks are generally optimistic about the company's future performance, further driving the stock price up. The pharmaceutical sector has recently corrected, with some stocks being undervalued.

CanSino Biologics rose 0.58%. Based on recent key news:

1. On November 13, CITIC Securities released a research report, stating that multiple products and indications under development by CanSino Biologics are about to be approved for market, and the existing R&D pipeline continues to expand, demonstrating long-term sustainable development capabilities. The approval of Edafo is contributing to the company's product sales, with stable growth in CanTian and increasing product sales revenue year by year. A "buy" rating was given, driving the stock price up. Source: Zhito Finance

2. On November 13, CanSino Biologics presented the final OS results of HARMONi-A at the 2025 SITC, with OSHR=0.74 for the Edafo treatment group and the control group, marking the world's first immunotherapy phase III clinical trial to achieve both clinical significance and statistical significance benefits in EGFRTKI-treated NSCLC PFS and OS This result enhances the market's confidence in the company's innovative drugs. Source: Zhitong Finance

3. On November 12, Morgan Stanley analyst Jack Lin maintained a buy rating on CanSino Biologics, with a target price of HKD 215. Analysts generally give strong buy ratings, further supporting the rise in stock prices. Source: Morgan Stanley The innovative drug market space in the biopharmaceutical industry is vast.

Stocks ranked among the top in industry market capitalization

Innovent Biologics rose 1.14%. Based on recent key news:

1. On November 13, Innovent Biologics plans to achieve revenue of 20 billion yuan in the next three years, with oncology drugs and comprehensive product lines each accounting for half, aiming to become a diversified enterprise. This strategy has boosted market confidence in its growth potential, driving up stock prices. Source: Yicai

2. On November 11, CMB International released a research report, giving Innovent Biologics a "buy" rating with a target price of HKD 110.62. This rating reflects the market's optimistic expectations for Innovent Biologics, further supporting the rise in stock prices. Source: Zhitong Finance

3. On November 11, the MSCI China Healthcare Index has risen 59.5% year-to-date, and the pharmaceutical sector remains attractive after a pullback. Innovent Biologics is considered undervalued, attracting investor attention. Source: Zhitong Finance The pharmaceutical sector's pullback has enhanced valuation attractiveness